Dopamine HCl Inj — Class II drug recall D-0853-2026
Ongoing recall by Pfizer, reported 2026-09-23, distributed nationwide. Lack of Assurance of Sterility
| Recall number | D-0853-2026 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Ongoing |
| Voluntary or mandated | Voluntary |
| Recalling firm | Pfizer, Manhattan, NY, United States |
| Recall initiated | 2026-09-04 |
| Classified | 2026-09-17 |
| Reported by FDA | 2026-09-23 |
| Distributed | Nationwide (US) |
| Reason classes | sterility |
| NDC | 00409-5820, 00409-5820-01, 00409-5820-11, 00409-9104, 00409-9104-20, 00409-9104-21 |
| Lot numbers | NL5230 |
| Expiration dates | 2027-10 |
Product
Dopamine HCl Inj., USP, 200 mg/5 mL (40 mg/mL), 5 mL Single-dose, 25 vials per tray, Rx only, Distributed by Hospira, Inc., Lake Forest, IL 60045 USA, Vial NDC 0409-5820-11, Carton NDC 0409-5820-01.
Reason for recall
Lack of Assurance of Sterility
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0853-2026. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-29. Not affiliated with or endorsed by FDA. Not medical or legal advice.